|
|
||||||||
1 Department of Animal Science and Faculty of Nutrition, Texas A&M University; 2 Cardiovascular Research Institute and Department of Medical Physiology, Texas A&M University System Health Science Center, College Station, Texas, 77843; and 3 Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261
| |
ABSTRACT |
|---|
|
|
|---|
Polyamines are essential for cell proliferation;
therefore, we hypothesized that arginase I or arginase II activities,
via production of ornithine for polyamine synthesis, may be limiting for proliferation of endothelial cells (EC). Bovine coronary venular EC
stably transfected with a lacZ gene (lacZ-EC, control), rat arginase I cDNA (AI-EC), or mouse arginase II cDNA (AII-EC) were utilized to test this hypothesis. Cell-proliferation assays showed that
EC proliferation was markedly increased in AI-EC and AII-EC compared
with lacZ-EC. Expression of proliferating cell nuclear antigen was also
enhanced in AI-EC and AII-EC. DL-
-difluoromethylornithine (DFMO), an
irreversible inhibitor of ornithine decarboxylase, was used to
establish that increased polyamine synthesis was involved in mediating
the enhanced growth of AI-EC and AII-EC. Addition of 5 mM DFMO to the
culture medium completely abolished the differences in cellular
putrescine concentrations and reduced the differences in spermidine
concentrations among AI-EC, AII-EC, and lacZ-EC. The DFMO treatment
also prevented an increase in AI-EC and AII-EC proliferation compared
with lacZ-EC. Addition of 10 and 50 µM putrescine dose-dependently
increased AI-EC, AII-EC, and lacZ-EC growth to the same extent. These
results demonstrate that either arginase isoform can potentially play a
role in modulating EC proliferation by regulating polyamine synthesis.
ornithine; polyamines; cell transfection
| |
INTRODUCTION |
|---|
|
|
|---|
ARGINASE IS
PHYSIOLOGICALLY the first enzyme for synthesis of polyamines
(putrescine, spermidine, and spermine) in mammalian cells (20,
30). Arginase hydrolyzes L-arginine into urea and L-ornithine, which is decarboxylated by ornithine
decarboxylase (ODC) to form putrescine. The latter is converted into
spermidine and spermine by spermidine synthase and spermine synthase,
respectively (Fig. 1). As polycationic
compounds, polyamines interact with nucleic acids, proteins, and other
negatively charged molecules and modulate their biosynthesis
(8). Thus polyamines are essential for cell growth and
function (6, 16, 27). When cells are stimulated with
growth factors, one of the first important events in cell proliferation
is the induction of polyamine synthesis, which precedes increases in
DNA replication as well as increases in RNA and protein syntheses
(6, 16). In contrast, depletion of cellular polyamines by
inhibition of arginase or ODC arrests cell growth (e.g., see Refs.
3, 9, 22, 24,
26, 28).
|
There are two distinct isoforms of arginase in mammalian cells (11, 32). Arginase I, which is colocalized with ODC and other polyamine synthetic enzymes in the cytosol, is highly expressed in the liver and to a much less extent in a few other tissues and cell types. Arginase II, a mitochondrial enzyme, is widely distributed in extrahepatic cells and tissues. These two isoforms are encoded by two different genes and differ in molecular and immunological properties, tissue distribution, subcellular location, and regulation of expression (11, 23). Recent studies have shown that altering expression of either arginase I (12, 14) or arginase II (14) can alter polyamine synthesis in macrophages and EC. These findings suggest the potential for an important role of the arginases in cell proliferation.
Proliferation of EC, an initial and necessary step in angiogenesis, is regulated by cellular polyamine levels (22, 26). Angiogenesis plays a key role both in physiological events such as wound healing and placental growth and in pathological conditions such as myocardial infarction, tumor growth, and diabetic retinopathy (2). Thus understanding and manipulating the growth of EC have important clinical implications. The objective of this study was to test the hypothesis that activities of arginase I or arginase II, via production of ornithine for polyamine synthesis, may be limiting for EC proliferation.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Materials.
Putrescine, spermidine, spermine, bovine serum albumin (BSA,
essentially fatty-acid free), and o-phthaldialdehyde were
obtained from Sigma-Aldrich (St. Louis, MO). Dulbecco's modified
Eagle's medium (DMEM), Dulbecco's phosphate-buffered saline
(DPBS), penicillin, streptomycin, and amphotericin B were obtained
from GIBCO (Grand Island, NY) and fetal bovine serum (FBS) from
Summit (Greeley, CO). HPLC-grade methanol and water were purchased from
Fisher Scientific (Houston, TX).
DL-
-difluoromethylornithine (DFMO) and G-418 sulfate
were obtained from Calbiochem (San Diego, CA) and a protease inhibitor
cocktail (Complete, Mini) from Roche Molecular Biochemicals
(Indianapolis, IN). Mouse monoclonal anti-proliferating cell nuclear
antigen (PCNA) antibody was purchased from Santa Cruz (Santa Cruz, CA)
and mouse monoclonal anti-actin from Sigma-Aldrich. Peroxidase-conjugated donkey anti-mouse IgG was obtained from Jackson (West Grove, PA).
Preparation and culture of stably transfected EC. Bovine coronary venular EC stably transfected with a lacZ gene (lacZ-EC, control), rat arginase I cDNA (AI-EC), or mouse arginase II cDNA (AII-EC) were produced and characterized as previously described (14). Transfected cells were cultured at 37°C in complete DMEM (DMEM with 20 mM D-glucose, 2 mM L-glutamine, 0.4 mM L-arginine, 100 U/ml penicillin, 100 µg/ml streptomycin, 0.25 µg/ml amphotericin B, and 600 µg/ml G-418) containing 10% FBS. Cells were passaged by trypsinization in Ca2+- and Mg2+-free DPBS containing 0.25% trypsin and 0.02% EDTA.
Cell-proliferation assays. Cell-proliferation assays were performed as described by Meininger and Wu (17). Briefly, transfected EC were seeded at 5,000 cells/cm2 in 24-well trays (day 0), and cells were cultured in complete DMEM containing 10% FBS for cell-proliferation assays. On days 2, 4, and 6, three wells of cells for each treatment group were trypsinized, and cell numbers were determined using a hemacytometer. In experiments to determine the effect of DFMO on cell proliferation, EC were first cultured for 24 h in serum-free DMEM to minimize cellular polyamines and then cultured for 4 days in complete DMEM containing 10% FBS and 0 or 5 mM DFMO or 5 mM DFMO plus 10 or 50 µM putrescine. The concentrations of DFMO and putrescine were chosen on the basis of previous studies with EC (22, 26). Culture medium was changed every other day in all experiments.
Western blot analysis of PCNA and actin. Western blot analysis of PCNA was performed as described by Meininger and Wu (17). Briefly, transfected EC were plated at 5,000 cells/cm2 in complete DMEM containing 10% FBS and cultured for 4 days. On day 4 of the culture, cells were lysed with a buffer consisting of 10 mM Tris · HCl (pH 8.0), 0.1% SDS, 1% sodium deoxycholate, 1% NP-40, 0.14 M NaCl, and a protease inhibitor cocktail. Protein concentration was determined using the bicinchoninic acid protocol (Pierce, Rockford, IL) with BSA as a standard. Total cell protein (10 µg) was loaded on a 9.5-16% gradient gel. To determine PCNA, the primary antibody (mouse monoclonal anti-PCNA) and the secondary antibody (peroxidase-labeled donkey anti-mouse IgG) were used at 1:1,000 and 1:30,000 dilutions, respectively. Peroxidase activity was visualized using a SuperSignal West Dura Extended Duration Substrate (Pierce) according to the manufacturer's instructions and by exposing blots to Kodak Biomax ML film (Kodak, Rochester, NY) for 1 min. For Western blot analysis of actin, the same blots used for PCNA analysis were washed with Restore Western Blot Stripping Buffer (Pierce). The primary antibody (mouse monoclonal anti-actin) and the secondary antibody (peroxidase-labeled donkey anti-mouse IgG) were used at 1:1,000 and 1:75,000 dilutions, respectively. Bands were visualized as described.
HPLC analysis of polyamines. Cellular concentrations of putrescine, spermidine, and spermine were determined by HPLC as previously described (29, 33). Briefly, 1 × 106 cells were lysed in 100 µl of 1.5 M HClO4 and then neutralized with 50 µl of 2 M K2CO3. The neutralized extracts were used for polyamine analysis by an ion-pairing HPLC method that involved precolumn derivatization with o-phthaldialdehyde. The assay mixture contained 10 µl of sample, 140 µl of HPLC water, and 10 µl of 1.2% benzoic acid (in 40 mM sodium borate, pH 9.5). An aliquot (25 µl) of the assay mixture was derivatized in an autosampler (model 712 WISP, Waters, Milford, MA) with 25 µl of 30 mM o-phthaldialdehyde (in 3.1% Brij-35, 50 mM 2-mercaptoethanol, and 40 mM sodium borate, pH 9.5), and 25 µl of the derivatized mixture was injected into a 3-µm reversed-phase C18 column (150 × 4.6 mm inside diameter) (Supelco, Bellefonte, PA). Polyamines were separated using a solvent gradient consisting of solution A (0.1 M sodium acetate, 4 mM SDS, 0.5% tetrahydrofuran, and 9% methanol, pH 7.2) and solution B (methanol and 4 mM SDS). Putrescine, spermidine, and spermine quantities in samples were measured by comparison with known amounts of authentic standards.
Statistical analysis. Data were analyzed by one-way ANOVA with Student-Newman-Keuls test for identifying differences among means, or by unpaired Student's t-test (25). P < 0.05 was taken to indicate statistical significance.
| |
RESULTS |
|---|
|
|
|---|
Effect of elevated arginase expression on cell proliferation.
AI-EC and AII-EC expressed high levels of arginase compared with
lacZ-EC (14). Elevated expression of arginase I or
arginase II markedly increased (P < 0.05) EC
proliferation (Fig. 2). For example, on
day 4 of the cell culture in complete DMEM containing 10%
FBS, cell numbers of AI-EC and AII-EC were increased (P < 0.05) by 69% and 75%, respectively, compared with lacZ-EC. There were no significant differences (P > 0.05) in cell
proliferation between AI-EC and AII-EC.
|
|
Effect of DFMO on cell proliferation and cellular polyamine
content.
To investigate whether the enhanced proliferation of AI-EC and AII-EC
was mediated by increased polyamine synthesis, the effects of DFMO (an
irreversible inhibitor of ODC) on EC proliferation and cellular
polyamine content were examined. After a 24-h period of culture in
serum-free medium, cellular polyamine concentrations reached basal
values and did not differ among AI-EC, AII-EC, and lacZ-EC (data not
shown). Cell-proliferation assays were then performed in compete DMEM
containing 10% FBS and 0 or 5 mM DFMO, or 5 mM DFMO plus 10 or 50 µM
putrescine. The addition of 5 mM DFMO abolished the increase in
proliferation of AI-EC and AII-EC compared with lacZ-EC (Fig.
4). The addition of putrescine to the
culture medium not only dose-dependently abolished (P < 0.05) the DFMO-dependent inhibition of proliferation but also
abolished any differences in proliferation among DMFO-treated lacZ-EC,
AI-EC, and AII-EC (Fig. 4). Addition of 10 µM putrescine restored
proliferation rates of all DFMO-treated EC lines to the level seen for
untreated lacZ-EC controls, which was similar to results observed in
studies using untransfected EC (22, 26). In the presence
of 50 µM putrescine, the proliferation of all DFMO-treated EC was
increased even further to rates similar to those for untreated AI-EC
and AII-EC (Fig. 4).
|
|
| |
DISCUSSION |
|---|
|
|
|---|
Besides playing an essential role in hepatic and intestinal urea synthesis from ammonia, arginase also may play a role in mammalian polyamine synthesis by producing L-ornithine as substrate for ODC (32). Our recent study has shown that overexpression of either arginase I or arginase II can enhance polyamine synthesis in EC (14). Likewise, overexpression of arginase I increases polyamine production in macrophages (12) and vascular smooth muscle cells (9, 28). In addition, induction of arginase II correlates with enhanced polyamine generation in enterocytes during weaning (30) or in the lactating mammary gland (19). Collectively, these findings suggest that intracellular L-ornithine availability is a limiting factor for polyamine synthesis in a wide variety of cell types and that both arginase isoforms have the ability to modulate polyamine synthesis. Although ODC is located in the cytosol, mitochondrially generated L-ornithine is available as substrate for this enzyme for polyamine synthesis in cells such as EC (this study) and enterocytes (29, 30), which is likely due to the presence of an L-ornithine transporter on the mitochondrial membrane (4, 10).
The essential role of polyamine synthesis in cell proliferation has been known for several decades (6). Elevated polyamine synthesis is an initial and necessary event in the cell cycle, and thus inhibition of polyamine synthesis arrests cell growth (16). A novel and important finding of this study is that expression of arginase I or arginase II can modulate EC proliferation on the basis of increases in both cell numbers (see Fig. 2) and PCNA expression (see Fig. 3) after overexpression of either arginase isoform. In agreement with these findings, arginase I expression was recently shown to be a limiting factor for the proliferation of vascular smooth muscle cells (9, 28). Although the present results are strong evidence for the role of arginase expression in cultured EC, we cannot state with certainty that arginase expression is limiting for EC proliferation in vivo. This matter will be addressed in future studies using mice with targeted knockout of arginase expression in EC.
To establish that elevated polyamine synthesis was involved in mediating the enhanced proliferation of AI-EC and AII-EC, the ODC inhibitor DFMO was employed. The addition of 5 mM DFMO to the culture medium markedly decreased intracellular putrescine and spermidine concentrations in EC, markedly reduced EC proliferation, and completely abolished any differences in the proliferation of AI-EC, AII-EC, and lacZ-EC. Furthermore, the addition of 10 or 50 µM putrescine to the culture medium dose-dependently restored the proliferation rates of DFMO-treated AI-EC, AII-EC, and lacZ-EC to the same extent (see Fig. 4), which indicates that there were no intrinsic differences in capability for proliferation among these cell lines. These data support our earlier conclusion that arginase can be a limiting factor for endothelial polyamine synthesis (14). Our findings also suggest that the increase in EC proliferation brought about by elevated arginase I or arginase II expression was mediated by an increase in polyamine synthesis as was recently shown for vascular smooth muscle cells (9, 28). A role for arginase in cell proliferation is also consistent with previous findings that 1) arginase-deficient Chinese hamster ovary cells could not grow in medium that lacked L-ornithine or polyamines (7), and 2) inhibition of arginase decreased the proliferation of the Caco-2 human colon carcinoma cell line (3) and the MDA-MB-468 human breast cancer cell line (24). Of note, under the present experimental conditions, spermine concentrations did not differ among AI-EC, AII-EC, and lacZ-EC, which indicates that spermine levels are not a determinant of EC proliferation rates.
Our findings may have important implications for EC proliferation under physiological and pathological conditions. Angiogenesis, the formation of new capillary blood vessels from preexisting microvessels, involves the migration and proliferation of EC, breakdown and reassembly of extracellular matrix, and construction of an endothelial tube (2). The essential role of polyamines in EC proliferation and angiogenesis has been well documented (1, 22, 26). Because we showed previously that elevated arginase expression in EC increased L-arginine-dependent synthesis of L-proline and polyamines (14), we also tested whether proline availability was limiting for EC proliferation rates. Addition of 0.1-2.0 mM L-proline to the tissue culture medium did not result in an increase in the growth of lacZ-EC, AI-EC, or AII-EC (13), which indicates that proliferation rates of AI-EC and AII-EC are not dependent on rates of proline synthesis.
It is noteworthy that arginase activity is severely deficient in EC of the spontaneously diabetic BB rat [an animal model of human type 1 diabetes mellitus (31)]. Interestingly, these cells also exhibit a marked impairment in proliferation (15). Arginase activity is also low in platelets of diabetic rats and humans compared with nondiabetic subjects (18). Because arginase can modulate EC proliferation through an increase in polyamine synthesis, elevating the expression of arginase I or arginase II in EC may provide a novel gene-therapy approach for improving angiogenesis and wound healing in diabetes mellitus.
Perspectives
Arginase is a major enzyme for providing intracellular ornithine for polyamine synthesis in many mammalian cells (32). Results of this study demonstrate that arginase I or II expression may be a limiting factor for EC proliferation. An increase in arginase activity results in enhanced synthesis of ornithine, polyamines, and proline (the major component of collagen) by EC (Ref. 14 as well as this study). As such, arginase may be a novel and attractive target for modulation of EC proliferation, angiogenesis, and vascular remodeling. An important application of this concept would be to enhance wound healing, improve microcirculatory function, and treat neovascular diseases. It therefore would be of great interest to investigate expression of endothelial arginase I and II in response to physiological and pathological factors that are known to promote or inhibit angiogenesis. Collectively, these studies may help establish an important but hitherto unrecognized role for arginase in the regulation of cardiovascular function.In conclusion, results of this study demonstrate for the first time that arginase is normally a limiting factor for endothelial cell proliferation. Consequently, elevated expression of either arginase I or arginase II results in enhanced EC proliferation via an increase in polyamine synthesis from L-arginine. As EC proliferation is an initial and necessary step in angiogenesis, regulation of arginase expression may have important implications for wound healing and cardiovascular function.
| |
ACKNOWLEDGEMENTS |
|---|
The authors thank Tony E. Haynes and Wene Yan for technical assistance and Frances Mutscher for office support.
| |
FOOTNOTES |
|---|
This work was supported in part by American Heart Associations Grants 95013030, 9740124N, and 98G-022 (to G. Wu and C. J. Meininger), Juvenile Diabetes Foundation International Grant 1-2000-437 (to C. J. Meininger and G. Wu), and National Institute of General Medical Science Grant R01 GM-57384 (to S. M. Morris, Jr.). G. Wu is an Established Investigator of the American Heart Association.
Address for reprint requests and other correspondence: G. Wu, Dept. of Animal Science, Texas A&M Univ., 2471 TAMU, College Station, TX 77843-2471 (E-mail: g-wu{at}tamu.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 6 June 2001; accepted in final form 30 August 2001.
| |
REFERENCES |
|---|
|
|
|---|
1.
Auvinen, M.
Cell transformation, invasion, and angiogenesis: a regulatory role for ornithine decarboxylase and polyamines?
J Natl Cancer Inst
89:
533-537,
1997
2.
Battegay, EJ.
Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects.
J Mol Med
73:
333-346,
1995[ISI][Medline].
3.
Buga, GM,
Wei LH,
Bauer PM,
Fukuto JM,
and
Ignarro LJ.
NG-hydroxy-L-arginine and nitric oxide inhibit Caco-2 tumor cell proliferation by distinct mechanisms.
Am J Physiol Regulatory Integrative Comp Physiol
275:
R1256-R1264,
1998
4.
Camacho, JA,
Obie C,
Biery B,
Goodman BK,
Hu CA,
Almashanu S,
Steel G,
Casey R,
Lambert M,
Mitchell GA,
and
Valle D.
Hyperornithinaemia-hyperammonaemia-homocitrullinemia syndrome is caused by mutations in a gene encoding a mitochondrial ornithine transporter.
Nat Genet
22:
151-158,
1999[ISI][Medline].
5.
Dietrich, DR.
Toxicological and pathological applications of proliferating cell nuclear antigen (PCNA), a novel endogenous marker for cell proliferation.
Crit Rev Toxicol
23:
77-109,
1993[ISI][Medline].
6.
Heby, O.
Role of polyamines in the control of cell proliferation and differentiation.
Differentiation
19:
1-20,
1980.
7.
Holtta, E,
and
Pohjanpelto P.
Polyamine dependence of Chinese hamster ovary cells in serum-free culture is due to deficient arginase activity.
Biochim Biophys Acta
721:
321-327,
1982[Medline].
8.
Igarashi, K,
and
Kashiwagi K.
Polyamines: mysterious modulators of cellular functions.
Biochem Biophys Res Commun
271:
559-564,
2000[ISI][Medline].
9.
Ignarro, LJ,
Buga GM,
Wei LH,
Bauer PM,
Wu G,
and
Del Soldato P.
Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation.
Proc Natl Acad Sci USA
98:
4202-4208,
2001
10.
Indiveri, C,
Tonazzi A,
Stipani I,
and
Palmieri F.
The purified and reconstituted ornithine/citrulline carrier from rat liver mitochondria catalyses a second transport mode: ornithine+/H+ exchange.
Biochem J
341:
705-711,
1999.
11.
Jenkinson, CP,
Grody WW,
and
Cederbaum SD.
Comparative properties of arginases.
Comp Biochem Physiol B Biochem Mol Biol
114:
107-132,
1996[Medline].
12.
Kepka-Lenhart, D,
Mistry SK,
Wu G,
and
Morris SM, Jr.
Arginase I: a limiting factor for nitric oxide and polyamine synthesis by activated macrophages?
Am J Physiol Regulatory Integrative Comp Physiol
279:
R2237-R2242,
2000
13.
Li, H.
Regulatory Role of Arginase I and II in Endothelial Arginine Metabolism and Cell Proliferation (PhD dissertation). College Station, TX: Texas A&M University, 2001, p. 160.
14.
Li, H,
Meininger CJ,
Hawker JR, Jr,
Haynes TE,
Kepka-Lenhart D,
Mistry SK,
Morris SM, Jr,
and
Wu G.
Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells.
Am J Physiol Endocrinol Metab
280:
E75-E82,
2001
15.
Marinos, RS,
Wei Z,
Wu G,
Kelly KA,
and
Meininger CJ.
Tetrahydrobiopterin levels regulate endothelial cell proliferation.
Am J Physiol Heart Circ Physiol
281:
H482-H489,
2001
16.
Marton, LJ,
and
Pegg AE.
Polyamines as targets for therapeutic intervention.
Annu Rev Pharmacol Toxicol
35:
55-91,
1995[ISI][Medline].
17.
Meininger CJ and Wu G. Regulation of endothelial cell
proliferation by nitric oxide. Methods Enzymol. In
press.
18.
Mendez, JD,
and
Zarzoza E.
Inhibition of platelet aggregation by L-arginine and polyamines in alloxan-treated rats.
Biochem Mol Biol Int
43:
311-318,
1997[ISI][Medline].
19.
Mezl, VA,
and
Knox WE.
Metabolism of arginine in lactating rat mammary gland.
Biochem J
166:
105-113,
1977[ISI][Medline].
20.
Morris, SM, Jr.
Arginine synthesis, metabolism, and transport: regulators of nitric oxide synthesis.
In: Cellular and Molecular Biology of Nitric Oxide, edited by Laskin JD,
and Laskin DL.. New York: Dekker, 1999, p. 57-85.
21.
Morris, SM, Jr,
Bhamidipati D,
and
Kepka-Lenhart D.
Human type II arginase: sequence analysis and tissue-specific expression.
Gene
193:
157-161,
1997[ISI][Medline].
22.
Morrison, RF,
and
Seidel ER.
Vascular endothelial cell proliferation: regulation of cellular polyamines.
Cardiovasc Res
29:
841-847,
1995[ISI][Medline].
23.
Shi, O,
Kepka-Lenhart D,
Morris SM, Jr,
and
O'Brien WE.
Structure of the murine arginase II gene.
Mamm Genome
9:
822-824,
1998[ISI][Medline].
24.
Singh, R,
Pervin S,
Karimi A,
Cederbaum S,
and
Chaudhuri G.
Arginase activity in human breast cancer cell lines: N
-hydroxyl-L-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells.
Cancer Res
60:
3305-3312,
2000
25.
Steel, RGD,
and
Torrie JH.
Principles and Procedures of Statistics. New York: McGraw-Hill, 1980.
26.
Takigawa, M,
Enomoto M,
Nishida Y,
Pan HO,
Kinoshita A,
and
Suzuki F.
Tumor angiogenesis and polyamines:
-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits B16 melanoma-induced angiogenesis in ovo and the proliferation of vascular endothelial cells in vitro.
Cancer Res
50:
4131-4138,
1990
27.
Wallace, HM.
The physiological role of the polyamines.
Eur J Clin Invest
30:
1-3,
2000[ISI][Medline].
28.
Wei, LH,
Wu G,
Morris SM, Jr,
and
Ignarro LJ.
Elevated arginase I expression in rat aortic smooth muscle cells increases cell proliferation.
Proc Natl Acad Sci USA
98:
9260-9264,
2001
29.
Wu, G,
Flynn NE,
and
Knabe DA.
Enhanced intestinal synthesis of polyamines from proline in cortisol-treated piglets.
Am J Physiol Endocrinol Metab
279:
E395-E402,
2000
30.
Wu, G,
Flynn NE,
Knabe DA,
and
Jaeger LA.
A cortisol surge mediates the enhanced polyamine synthesis in porcine enterocytes during weaning.
Am J Physiol Regulatory Integrative Comp Physiol
279:
R554-R559,
2000
31.
Wu, G,
and
Meininger CJ.
Impaired arginine metabolism and NO synthesis in coronary endothelial cells of the spontaneously diabetic BB rat.
Am J Physiol Heart Circ Physiol
269:
H1312-H1318,
1995
32.
Wu, G,
and
Morris SM, Jr.
Arginine metabolism: nitric oxide and beyond.
Biochem J
336:
1-17,
1998.
33.
Wu, G,
Pond WG,
Flynn SP,
Ott TL,
and
Bazer FW.
Maternal dietary protein deficiency decreases nitric oxide synthase and ornithine decarboxylase activities in placenta and endometrium of pigs during early gestation.
J Nutr
128:
2395-2402,
1998
This article has been cited by other articles:
![]() |
L. D. Nelin, X. Wang, Q. Zhao, L. G. Chicoine, T. L. Young, D. M. Hatch, B. K. English, and Y. Liu MKP-1 switches arginine metabolism from nitric oxide synthase to arginase following endotoxin challenge Am J Physiol Cell Physiol, August 1, 2007; 293(2): C632 - C640. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Morris Jr. Arginine Metabolism: Boundaries of Our Knowledge J. Nutr., June 1, 2007; 137(6): 1602S - 1609S. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Horowitz, D. G. Binion, V. M. Nelson, Y. Kanaa, P. Javadi, Z. Lazarova, C. Andrekopoulos, B. Kalyanaraman, M. F. Otterson, and P. Rafiee Increased arginase activity and endothelial dysfunction in human inflammatory bowel disease Am J Physiol Gastrointest Liver Physiol, May 1, 2007; 292(5): G1323 - G1336. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. P. Stanley, L. G. Chicoine, T. L. Young, K. M. Reber, C. R. Lyons, Y. Liu, and L. D. Nelin Gene transfer with inducible nitric oxide synthase decreases production of urea by arginase in pulmonary arterial endothelial cells Am J Physiol Lung Cell Mol Physiol, February 1, 2006; 290(2): L298 - L306. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. D. Nelin, L. G. Chicoine, K. M. Reber, B. K. English, T. L. Young, and Y. Liu Cytokine-Induced Endothelial Arginase Expression Is Dependent on Epidermal Growth Factor Receptor Am. J. Respir. Cell Mol. Biol., October 1, 2005; 33(4): 394 - 401. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. E. King, M. E. Rothenberg, and N. Zimmermann Arginine in Asthma and Lung Inflammation J. Nutr., October 1, 2004; 134(10): 2830S - 2836S. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. G. Chicoine, M. L. Paffett, T. L. Young, and L. D. Nelin Arginase inhibition increases nitric oxide production in bovine pulmonary arterial endothelial cells Am J Physiol Lung Cell Mol Physiol, July 1, 2004; 287(1): L60 - L68. [Abstract] [Full Text] [PDF] |
||||
![]() |
J M Rhoads, W Chen, J Gookin, G Y Wu, Q Fu, A T Blikslager, R A Rippe, R A Argenzio, W G Cance, E M Weaver, et al. Arginine stimulates intestinal cell migration through a focal adhesion kinase dependent mechanism Gut, April 1, 2004; 53(4): 514 - 522. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Bivalacqua, M. F. Usta, H. C. Champion, P. J. Kadowitz, and W. J. G. Hellstrom Endothelial Dysfunction in Erectile Dysfunction: Role of the Endothelium in Erectile Physiology and Disease J Androl, November 1, 2003; 24(6_suppl): S17 - S37. [Full Text] [PDF] |
||||
![]() |
B. B. Childress and J. K. Stechmiller Role of Nitric Oxide in Wound Healing Biol Res Nurs, July 1, 2002; 4(1): 5 - 15. [Abstract] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |